Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, ...

They have at least one thing in common: An exciting pipeline.